Allegion signals 2026 adjusted EPS of $8.85-$9.00 as it raises reported revenue outlook to 7.5%-8.5%
Seeking Alpha ·
Earnings Call Insights: Allegion (ALLE) Q2 2026 "Second quarter results were driven by strong organic growth in the Americas, and we see continued momentum in nonresidential indicators." (President, CEO & Director John Stone)
AI 시장 분석
Allergan expects 2026 adjusted EPS at $8.85-$9.00 and increased reported revenue guidance by 7.5-8.5%. US organic growth and continued momentum in non-residential indices have contributed to earnings.
상승 영향
- Semiconductors — Allergan's recovery in non-residential construction and renovation market may positively impact the semiconductor sector as various equipment and systems used in non-residential construction and renovation rely on semiconductors.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
496 participants
Related News
- Chinese titanium suppliers target Western aerospace buyers at Farnborough
- West Pharmaceutical signals 10%-11% 2026 organic revenue growth and $8.85-$9.05 adjusted EPS amid leadership transition
- Nasdaq-100 plunges 2% as oil tops $100 amid Middle East tensions
- Dime commercial bancshares targets over 3.50% NIM by Q4 2027 as it plans to resume buybacks in Q3
- Colony Bank targets disciplined pricing as 2026 loan growth could slip slightly below 8% while First Reliance close remains set for Q4
- Pzena Investment Management adds CDW
